Latest Capital Raising News

Adriatic Metals has announced a two-tranche institutional placement to raise A$80 million, aiming to fast-track the expansion of its Vares Processing Plant and strengthen its balance sheet ahead of commercial production.

Antilles Gold Limited is raising $1 million through a share and option placement to support working capital and development of its Nueva Sabana copper-gold mine in Cuba.

Environmental Clean Technologies Limited (ECT) has raised $750,000 through a two-tranche placement to fund its innovative COLDry Fertiliser Project and pursue strategic acquisitions, alongside key board changes.

Rapid Lithium has successfully placed the full $1 million shortfall from its recent entitlement issue, positioning the company to advance exploration projects in Canada and the USA.

Dexus (ASX: DXS) reports a statutory net profit of $10.3 million for the half-year ending December 2024, rebounding from a significant loss last year, while navigating challenges from higher interest rates and lower trading profits.

Polymetals Resources Ltd invites eligible shareholders to participate in a new Share Purchase Plan at $0.80 per share, aiming to raise up to $3.2 million after a successful $35 million institutional placement.

Ausmon Resources Limited has launched a Share Purchase Plan aiming to raise up to $540,000 by issuing shares at a discounted price, supporting its exploration and operational funding needs.

Polymetals Resources Ltd has opened a Share Purchase Plan allowing eligible shareholders to invest up to $30,000 each at $0.80 per share, aiming to raise $3.2 million to bolster its balance sheet and fund exploration.

Artemis Resources has completed the second tranche of a $4 million capital raise, enabling the resumption of drilling at its Karratha Gold Project after cyclone-related delays.

Ausmon Resources Limited has announced a Share Purchase Plan offering up to 300 million shares at a discounted price to raise $540,000, aiming to reduce borrowings and fund exploration activities.

Icetana Limited has successfully closed its renounceable pro rata entitlement offer, raising $629,422 through new share issuance, with convertible notes poised to convert into shares shortly.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.